More breakthroughs in the medical research field: Salt Lake City-based specialty pharmaceutical company Lipocine Inc. (NASDAQ:LPCN) announced Thursday it’s been picked to present LPCN 1144 clinical results as part of ENDO 2019, being held next weekend in New Orleans.
A news release out Thursday said the presentation will highlight the therapeutic potential of LPCN 1144 in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Lipocine is in the business of developing innovative pharmaceutical products for use in men's and women's health using its proprietary drug delivery technologies. Its flagship product, TLANDO, a novel oral prodrug of testosterone containing what's called testosterone undecanoate, is designed to help restore normal testosterone levels in hypogonadal men.
Shares in Lipocine rocketed 13 cents, or 6.5%, to $2.16, on share volume of 229,000.
Related Stories
